The insulin delivery devices market has achieved a significant milestone, reaching US$ 16.8 Billion in 2023. Furthermore, it is projected to attain a valuation of US$ 33.1 Billion by the end of 2033, with a remarkable compound annual growth rate (CAGR) of 7% during the forecast period from 2023 to 2033.
The insulin delivery devices market primarily consists of devices like insulin pens, insulin pumps, insulin syringes, and insulin jet injectors. These devices provide a convenient and precise means of insulin administration, thus improving the quality of life for individuals with diabetes. Insulin pens, in particular, have gained popularity for their ease of use, accuracy, and portability, as they eliminate the need for traditional vial-and-syringe methods.
Get Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=5105
Market Opportunity:
The market offers substantial opportunities, driven by the escalating demand for improved insulin delivery methods, especially among the elderly population. Diabetes management is essential to prevent complications, making patients and healthcare providers increasingly open to adopting advanced delivery devices. Additionally, technological advancements, such as connected insulin pens and smart insulin pumps, have revolutionized diabetes care, enhancing patient compliance and disease management. The market is poised to capitalize on these innovations as they gain widespread acceptance.
Market Challenges:
Despite the promising outlook, the insulin delivery devices market faces several challenges. One of the foremost hurdles is the high cost associated with some advanced devices. This poses a barrier to entry for individuals in lower-income brackets. Furthermore, there is a need for better education and awareness about the available devices, as many individuals may not be aware of or fully understand the benefits of these modern insulin delivery tools. Regulatory approvals, quality control, and the risk of device-related complications also pose ongoing challenges for the market.
Key Players:
- Becton, Dickinson and Company
- SOOIL Development Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Owen Mumford Ltd.
- Insulet Corporation
- Sanofi S.A.
- Mannkind Corporation
- Yepsomed Holding AG
- B. Braun Melsungen AG
- Novo Nordisk A/S
- Valeritas Inc.
- Eli Lilly and Company
- Biocon Ltd.
- Cellnova Group SA
- Medtronic plc
- Tandem Diabetes Care Inc.
Competitive Landscape:
In May 2022, MannKind Corporation, a prominent biopharmaceutical organization, entered into an agreement to acquire the V-Go insulin delivery device technology from Zealand Pharma for a sum of US$ 10 million, in addition to sales-based milestone capital. This strategic acquisition not only bolstered MannKind’s market presence on a global scale but also expanded its already diverse product portfolio.
Similarly, Tandem Diabetes Care, an esteemed American medical device manufacturer, made an announcement in December 2022 regarding its acquisition of AMF Medical, a Switzerland-based company. The deal, valued at US$ 216 million, included additional payouts based on predetermined milestones. This acquisition further solidified Tandem Diabetes Care’s position in the industry and reinforced its commitment to delivering innovative medical solutions.
By actively pursuing collaborations, mergers, and acquisitions, leading insulin delivery device companies are actively expanding their product offerings and strengthening their foothold in the global market. These strategic moves not only enhance their market presence but also enable them to meet the evolving needs of patients worldwide.
Key Segments of Insulin Delivery Devices Industry Research
- By Product Type :
- Insulin Pens
- Insulin Syringes
- Insulin Pumps
- Others
- By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Sales
- Diabetes Clinics/Centers
- By Region :
- North America
- Latin America
- Europe
- APAC
- MEA
Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=RC&rep_id=5105
About Fact.MR :
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.
Contact:
US Sales Office
11140 Rockville Pike
Suite 400 Rockville, MD 20852
United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Sales Team: sales@factmr.com
Follow Us: LinkedIn | Twitter | YouTube